|
1
|
Papatheodoridis GV, Dalekos GN, Yurdaydin
C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G,
Gatselis N, et al: Incidence and predictors of hepatocellular
carcinoma in Caucasian chronic hepatitis B patients receiving
entecavir or tenofovir. J Hepatol. 62:363–370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen WX, Zhang ZG, Ding ZY, Liang HF, Song
J, Tan XL, Wu JJ, Li GZ, Zeng Z, Zhang BX, et al: MicroRNA-630
suppresses tumor metastasis through the TGF-β-miR-630-Slug
signaling pathway and correlates inversely with poor prognosis in
hepatocellular carcinoma. Oncotarget. 7:22674–22686.
2016.PubMed/NCBI
|
|
3
|
Xu MY, Chen R, Yu JX, Liu T, Qu Y and Lu
LG: AZGP1 suppresses epithelial-to-mesenchymal transition and
hepatic carcinogenesis by blocking TGFβ1-ERK2 pathways. Cancer
Lett. 374:241–249. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferroudj S, Yildiz G, Bouras M, Iscan E,
Ekin U and Ozturk M: Role of fanconi anemia/BRCA pathway genes in
hepatocellular carcinoma chemoresistance. Hepatol Res. Feb
16–2016.(Epub ahead of print). doi: 10.1111/hepr.12675. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ono R, Kobayashi S, Wagatsuma H, Aisaka K,
Kohda T, Kaneko-Ishino T and Ishino F: A retrotransposon-derived
gene, PEG10, is a novel imprinted gene located on human chromosome
7q21. Genomics. 73:232–237. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li CM, Margolin AA, Salas M, Memeo L,
Mansukhani M, Hibshoosh H, Szabolcs M, Klinakis A and Tycko B:
PEG10 is a c-MYC target gene in cancer cells. Cancer Res.
66:665–672. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bang H, Ha SY, Hwang SH and Park CK:
Expression of PEG10 is associated with poor survival and tumor
recurrence in hepatocellular carcinoma. Cancer Res Treat.
47:844–852. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deng X, Hu Y, Ding Q, Han R, Guo Q, Qin J,
Li J, Xiao R, Tian S, Hu W, et al: PEG10 plays a crucial role in
human lung cancer proliferation, progression, prognosis and
metastasis. Oncol Rep. 32:2159–2167. 2014.PubMed/NCBI
|
|
9
|
Li X, Xiao R, Tembo K, Hao L, Xiong M, Pan
S, Yang X, Yuan W, Xiong J and Zhang Q: PEG10 promotes human breast
cancer cell proliferation, migration and invasion. Int J Oncol.
48:1933–1942. 2016.PubMed/NCBI
|
|
10
|
Akamatsu S, Wyatt AW, Lin D, Lysakowski S,
Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A, et al: The
placental gene PEG10 promotes progression of neuroendocrine
prostate cancer. Cell Rep. 12:922–936. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xiong J, Qin J, Zheng Y, Peng X, Luo Y and
Meng X: PEG10 promotes the migration of human Burkitts lymphoma
cells by up-regulating the expression of matrix metalloproteinase-2
and −9. Clin Invest Med. 35:E117–E125. 2012.PubMed/NCBI
|
|
12
|
Li X, Zheng L, Zhang F, Hu J, Chou J, Liu
Y, Xing Y and Xi T: STARD13-correlated ceRNA network inhibits EMT
and metastasis of breast cancer. Oncotarget. 7:23197–23211.
2016.PubMed/NCBI
|
|
13
|
Da C, Liu Y, Zhan Y, Liu K and Wang R:
Nobiletin inhibits epithelial-mesenchymal transition of human
non-small cell lung cancer cells by antagonizing the TGF-β1/Smad3
signaling pathway. Oncol Rep. 35:2767–2774. 2016.PubMed/NCBI
|
|
14
|
Dong Z, Tai W, Lei W, Wang Y, Li Z and
Zhang T: IL-27 inhibits the TGF-β1-induced epithelial-mesenchymal
transition in alveolar epithelial cells. BMC Cell Biol. 17:72016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li GC, Ye QH, Dong QZ, Ren N, Jia HL and
Qin LX: TGF beta1 and related-Smads contribute to pulmonary
metastasis of hepatocellular carcinoma in mice model. J Exp Clin
Cancer Res. 31:932010. View Article : Google Scholar
|
|
16
|
Ma H, Gao L, Li S, Qin J, Chen L, Liu X,
Xu P, Wang F, Xiao H, Zhou S, et al: CCR7 enhances TGF-β1-induced
epithelial-mesenchymal transition and is associated with lymph node
metastasis and poor overall survival in gastric cancer. Oncotarget.
6:24348–24360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang J, Li T, Gao C, Lv X, Liu K, Song H,
Xing Y and Xi T: FOXO1 3UTR functions as a ceRNA in repressing the
metastases of breast cancer cells via regulating miRNA activity.
FEBS Lett. 588:3218–3224. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng L, Li X, Meng X, Chou J, Hu J, Zhang
F, Zhang Z, Xing Y, Liu Y and Xi T: Competing endogenous RNA
networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen
resistance in breast cancer. Mol Cell Endocrinol. 427:133–142.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu T, Zhang J, Chen W, Pan S, Zhi X, Wen
L, Zhou Y, Chen BW, Qiu J, Zhang Y, et al: ARK5 promotes
doxorubicin resistance in hepatocellular carcinoma via
epithelial-mesenchymal transition. Cancer Lett. 377:140–148. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu DC, Yang ZL and Jiang S:
Identification of PEG10 and TSG101 as carcinogenesis, progression,
and poor-prognosis related biomarkers for gallbladder
adenocarcinoma. Pathol Oncol Res. 17:859–866. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peng W, Zhao G, Ma Y, Yu H and Wang X:
Dendritic cells transfected with PEG10 recombinant adenovirus
elicit anti-tumor immune response in vitro and in vivo. Vaccine.
29:3501–3506. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu K, Guo L, Guo Y, Zhou B, Li T, Yang H,
Yin R and Xi T: AEG-1 3-untranslated region functions as a ceRNA in
inducing epithelial-mesenchymal transition of human non-small cell
lung cancer by regulating miR-30a activity. Eur J Cell Biol.
94:22–31. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jie X, Lang C, Jian Q, Chaoqun L, Dehua Y,
Yi S, Yanping J, Luokun X, Qiuping Z, Hui W, et al: Androgen
activates PEG10 to promote carcinogenesis in hepatic cancer cells.
Oncogene. 26:5741–5751. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ip WK, Lai PB, Wong NL, Sy SM, Beheshti B,
Squire JA and Wong N: Identification of PEG10 as a progression
related biomarker for hepatocellular carcinoma. Cancer Lett.
250:284–291. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng X, Carstens JL, Kim J, Scheible M,
Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R:
Epithelial-to-mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Nature.
527:525–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fischer KR, Durrans A, Lee S, Sheng J, Li
F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, et al:
Epithelial-to-mesenchymal transition is not required for lung
metastasis but contributes to chemoresistance. Nature. 527:472–476.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bharti R, Dey G and Mandal M: Cancer
development, chemoresistance, epithelial to mesenchymal transition
and stem cells: A snapshot of IL-6 mediated involvement. Cancer
Lett. 375:51–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cañadas I, Rojo F, Taus Á, Arpí O,
Arumí-Uría M, Pijuan L, Menéndez S, Zazo S, Dómine M, Salido M, et
al: Targeting epithelial-to-mesenchymal transition with Met
inhibitors reverts chemoresistance in small cell lung cancer. Clin
Cancer Res. 20:938–950. 2014. View Article : Google Scholar : PubMed/NCBI
|
